Opinion|Videos|December 30, 2024
Improving Transitions of Care for Patients Receiving Bispecific Therapies and Final Recommendations
Key Takeaways
- Weekly dosing may provide consistent therapeutic levels, while biweekly dosing reduces hospital visits, affecting patient convenience and healthcare resource allocation.
- Formulary decisions should evaluate efficacy, safety profiles, cost-effectiveness, and integration potential into existing treatment regimens.
Panelists discuss how key recommendations for optimizing bispecific therapy care focus on establishing robust communication protocols between academic and community centers while ensuring community centers develop comprehensive infrastructure including staff training, emergency protocols, and care coordination pathways.
Advertisement
Episodes in this series
Video content above is prompted by the following
- What recommendations do you have for improving the transitions of care between academic and community centers for patients receiving bispecific therapies?
- What additional recommendations do you have for community centers building a bispecific therapy program?
Advertisement
Related to this article
Rather than requiring a new trial, the FDA extended evidence from carcinoma in situ to high-grade papillary-only disease, a new approach for this setting.
Pharmacists can address patient fears about fentanyl by distinguishing illicit from prescribed opioids and promoting safe, empathetic, evidence-based opioid use.
Nationwide Danish data presented at EASD 2026 link a widening cancer gap in type 2 diabetes largely to obesity-related cancers.
Each October, the pharmacy profession pauses to recognize technicians' decades-long evolution, from on-the-job trainees to nationally certified health care professionals.
Peer Reviewed
Creating institution-specific, literacy-friendly chemotherapy education sheets resulted in patient education materials with higher readability scores than similar materials from common chemotherapy education sites.
In an era of rapidly evolving technology, we remain in a people-powered world.
Victoria P. Werth, MD, discusses how litifilimab’s 52-week AMETHYST findings inform treatment expectations and timely reassessment of persistent cutaneous lupus symptoms.
In an interview with Pharmacy Times, Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania and chief of dermatology at the Philadelphia VA Medical Center, discusses why meaningful improvement extends beyond skin clearance and how response timing affects patients with difficult-to-control disease.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Preparing Pharmacists for Psychedelic Medicine
2
National Pharmacy Technician Day: Celebrating the Backbone of Pharmacy
3
Pneumonic Plague: What Pharmacists Need to Know About Treatment
4
Cemdisiran’s Potential to Reduce Hospitalizations in Myasthenia Gravis
5